Background: Chronic opioid exposure is common world-wide, but behavioural performance remain
Introduction
Working memory is a limited capacity cognitive system that functions to hold information in an active manner to facilitate the performance of complex cognitive tasks (Miyake & Shah, 1999). Such tasks include, for example, language comprehension, learning, abstract thinking (Twamley et al. problem-solving (Westen, 2006) , understanding the meaning of complex texts and planning verbal communications (Zihl et al. 1979) . Working memory (WM) is limited in both capacity and duration and is often used synonymously, but inaccurately, with the term "short term memory" There are a few brain imaging studies on visuospatial memory impairments among drug users.
2006),
Kubler and colleagues reported that cocaine dependent individuals were impaired in visuospatial working memory. These were associated with prefrontal, cingulate and striatal regions (Kubler et al.
2005).
In another study opiate dependent individuals were impaired in working memory-related brain areas (Bach et al, 2012).
Hyman and colleagues have conceptualised the behavioural phenomena typically described as 'addiction' to a "pathological usurpation of the neural mechanisms of learning and memory that under normal circumstances serve to shape survival behaviours related to the pursuit of rewards and the cues that predict them" (Hyman. 
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The present study aimed to extend our understanding of neurocognitive performance in dependent and non-dependent opioid users, focusing on visuospatial memory function. Employing an ambispective cohort design, we tested representative samples of male participants exposed to illicit and therapeutic opioid drugs and matched, non-substance using, healthy controls. Specifically, the study aimed to determine if performance on tasks measuring visuospatial memory, especially delayed memory performance, which is very sensitive for the varying of 'executive demands', was affected by (1) the type of the opioid exposure (methadone vs. heroin) at different stages of treatment seeking, (2) the context (opioids prescribed for pain control compared with illicit opioids) and (3) the presence or absence of syndromal opioid dependence (opioid dependent compared to non-opioid users) and (4) administration route -injection status (opioid dependent and injecting compared with dependent and non-injecting participants). We have previously identified and reported differential effects of heroin, methadone and prescribed analgesic medication on neurocognitive measures of impulsivity (Baldacchino et al. 2014) from the same study cohort.
Method

Participants
Ethical permission for the conduct of this study was provided by the East of Scotland Research Ethics Service (REC reference number: 06/S1401/32). A full description of the participants can be found in Baldacchino et al (2014). Male only participants were recruited from UK NHS substance misuse and pain management services. A control group of healthy participants was also recruited. All participants were screened to exclude lifetime or current histories of psychosis, PTSD, neurological and neurodevelopmental disorders, borderline or psychopathic personality disorders, head injuries; individuals with a lifetime history of non-fatal overdose episodes requiring medical attention (e.g. ambulance call out, CPR), co-occurring benzodiazepine, psychostimulant and alcohol dependence. All participants were screened by an experienced clinician (AB) for acute opioid and opioid withdrawal symptoms prior to the neuropsychological testing.
The Heroin group (H) (N=24) were 'first time' referrals to a structured Methadone Maintenance Treatment (MMT) programme. The Methadone group (M) (N=29) were established and stable participants in a MMT programme with objective confirmation of absence of illicit drug use for more than six months. Eighteen of the twenty-nine MMT group participants who showed objective continuing clinical stability were retested six months after baseline testing. All recruits making up the H and MMT cohorts presented initially with opioid dependence and reported a history of more than three years of continuous and daily illicit opioid use.
Heroin participants (H) performed repeated neuropsychological testing during a single blinded procedure that permitted the objective observation of participants (a) 3-5 hours after their last illicit heroin administration to minimise the confounding cognitive effects of acute intoxication; (b) 10-15 hours after the last heroin dose in a state of controlled opioid withdrawal and subsequently (c) following more than two weeks on a stable dose of MMT. Clinically this is known as tolerance testing which is a single-blinded procedure that permitted the objective observation of individuals during stages of acute intoxication, withdrawal and subsequent stabilisation on a fixed dose methadone within a period of 7-14 days (Baldacchino, 2011).
The two opioid dependent groups (H and M groups) were matched for lifetime drug use history, morphine equivalent dosages and other drug use (including tobacco smoking) history 30 days prior to baseline testing. The CANTAB neuropsychological tests presented here refer to the standard tests selected from the batteries used at baseline testing. Where available, parallel versions of the tasks were used with the same participant to minimise practice effects.
This approach offered the opportunity to test whether any visuospatial memory measures that differed from those of control participants represented a stable phenomenon, or could be modified by differential opioid exposure and switch to an alternate opioid (MMT). A cohort of non-dependent participants prescribed opioids for chronic pain for more than 3 years (P) (N=28) with no history of 'illicit' opioid use, or methadone treatment, was also recruited. This group were prescribed tramadol, codeine, or both, for moderate chronic pain. Both P and HC groups were tested only once ( 
Data Analysis
Data meeting assumptions of normality and homogeneity of variance were analysed using ANOVA (Winer et al. 1991) . All other data were compared using appropriate non-parametric tests (e.g.
Kruskal-Wallis and Mann-Whitney tests). Preliminary analysis of all the experimental and control groups separately indicated that the samples did not come from normally distributed populations with the same standard deviation. A planned (a priori) contrasts analysis was, therefore, run to test for significant differences between the four independent study groups. Mann Whitney U tests established that NART, age, morphine equivalent dosage and previous alcohol use all needed to be used as covariates for further analyses.
Mann Whitney U tests were also performed to examine: (a) sociodemographic characteristics for participants in the H group, comparing those who experienced the lowest (n=8) and highest (n=8) scores on the COWS. Similarly, the same test was used to determine if there were differences between the H group of participants who were tested at baseline and those who were followed up and tested in withdrawal and, subsequently, on methadone. (b) sociodemographic characteristics for participants in the MMT group, comparing those tested at baseline (n=29) and those followed up after six months (n=18). (c) sociodemographic characteristics for participants in the H and M groups comparing those with a lifetime subjective history of injecting illicit opioids (n=41) and those with no history of injecting (n=11). A high COWS score was defined as a score between 18-25; a low COWS score was defined as a score 8-14.
The data were first analysed using an omnibus test to determine if significant differences existed between the groups. If the test revealed significance, appropriate pair wise comparisons were performed. In order to control for family wise error, post hoc Bonferroni corrected pairwise comparisons was used (Fields, 2009) . P values <0.01 were considered significant. This minimised the effects of multiple comparisons, subgroup analyses and/or repeated measures as we were considering a family of statistical inferences simultaneously (Sainani, 2009). Those reported as between p<0.05 and p>0.01 are presented as non-significant trends when they are considered relevant to substantiate the interpretation of other significant results.
ANCOVA was used to test for group differences with respect to visuospatial memory performance measures. The PRM and SWM outcomes did not meet assumptions of normality and were square root transformed prior to performing the ANCOVA. However, PAL outcomes were log 10 transformed prior to performing the ANCOVA. For incremental levels of difficulty within the testing sessions, the within-subject factor DIFFICULTY was introduced, (e.g. SWM (between/within search errors), SSP (span length between 1-9), DMS (0, 4 and 12 second delays), and PAL (1, 2, 3, 6, or 8 shapes)).
Homogeneity of variance was assessed using the Mauchly Sphericity Test. Where data sets significantly (p<0.05) violated this requirement, the Greenhouse Geisser Epsilon (^ε) correction parameter for degrees of freedom was used to calculate a more conservative p value for each F ratio.
Further a priori subgroup analyses were conducted using (1) a two-group factor reflecting DEPENDENCE status (H and M groups vs P and HC groups) and (2) a two-group factor reflecting INJECTING status (H and M injecting vs. H and M never injecting groups) separately as between subject factors. Importantly, we had specific a priori hypotheses about the impact of dependence for the H and M groups, however we could not draw any particular conclusion about the exposure of the opiate use. In addition, we used DEPENDENCE as a proxy clinical measure of severity without any biological basis.
Similarly, repeated measures ANCOVA was used to evaluate all neuropsychological performance measures between the H group at baseline, in controlled opioid withdrawal and subsequently when stabilised on methadone with presumed opioid receptor occupancy state as a within-subjects factor.
Similarly, repeated measures ANCOVA was performed for the M group at baseline and at six months follow up with duration as a within-subjects factor.
All analyses were conducted using SPSS for Windows (v.18, SPSS Inc. Chicago, Ill.).
Results
Demographic characteristics
A description of demographics, drug use and smoking variables for the four groups is presented in Table 3 . The H and M groups differed from the P and HC groups with respect to several clinical characteristics. Opioid dependent participants started to drink alcohol approximately two years earlier than the other groups. The mean morphine equivalent daily dose for the P group was significantly lower (59.1 mg) than the H and M groups (165.9mg) (p<0.001).
INSERT TABLE 3 here
When comparing high against low scores for COWS in the H group, there were no differences between age (p=0.88), SIMD score (p=0.75), years in education (p=0.38), years when starting using alcohol (p=0.07), alcohol amount used in last month (p=0.87) or current level of nicotine dependence (Fagerström scores) (p=0.96) Similarly, there were no group differences identified on these measures when comparing H group tested at baseline and those retested either through the tolerance testing protocol six months later when taking methadone. There were no significant differences with demographic and drug use characteristics between injecting participants (n=43) and non-injecting participants (n=10). However, NART scores were significantly higher (p<0.01) in the injecting group.
Visual Memory Performance on DMS
There was a significant effect on the percentage of correct responses [GROUP F (3,100) =10.3, p<0.001]. There were no significant performance differences between groups with respect to the simultaneous matching condition. Post hoc Bonferroni comparisons, however, showed participants from the H group made significantly more errors than (a) the HC group at the 0 (p<0.005), 4 (p<0.001) and 12 second (p<0.001) delay stages, (b) the P group for the 4 (p<0.01) and 12 (p<0.005) second delay stages and (c) the M group for 0 (p<0.005), 4 (p<0.005) and 12 (p<0.001) second delay stages (Figure 1) . In summary the H group exhibited significant delay-dependent memory impairment when compared with the comparison and control groups.
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Performance on PRM, SRM and PAL
There were no significant GROUP effects on the number of correct trials [F<1] and mean response latencies [F<1] on the PAL and PRM tests. There was a non-significant GROUP trend on the total number of correct trials [F (3,102) = 3.6, p=0.02] on the SRM only.
Spatial memory
Performance on SSP
There was a significant GROUP [F (3,102) =16.8, p<0.001] effect for total errors. Post hoc Bonferroni comparisons showed that the participants from the H group significantly made more errors compared to the M (p<0.001, d=1.25) and HC (p<0.005, d=1.14) groups (Figure 2) . The total error score for the P group lay between those of the H, M and HC groups and did not differ significantly from any of the other three groups (p=1.0).
There was also a significant GROUP [F (3,101) 
INSERT FIGURE 2 here
Performance on SWM
There was a non-significant GROUP trend for: total mean errors [F(3,102) Type of the opioid exposure at different stages of treatment and visuospatial memory performance.
When the H group was tested during different states of opioid exposure (tolerance testing) there was a significant effect of on the DMS mean correct latency [F (2, 34.22)=10.5, p<0.001] . Post hoc Bonferroni comparisons showed a significant improvement at the 12 second delay stage (p<0.001) but not the 0 second and 4 second delay conditions. These improvements were noted in comparison with the stable MMT, the 'withdrawal' stage (p<0.005) and the illicit heroin stage (p<0.001). There was no effect on PRM, SRM, PAL , SSP and SWM outcomes.
There was a trend (p<0.05) for the M group to improve on DMS and SWM outcomes in selecting the right stimulus following prolonged exposure to a stable dose of methadone. There were no significant additional effects on all PRM, SRM, PAL, and SSP outcomes in the M group following prolonged exposure to a stable dose of methadone.
Discussion
This study identified differential effects of chronic heroin and methadone exposures on neuropsychological measures of visuospatial memory that were independent of estimates of addiction severity (injecting behaviour, dependence status). The study also identified an improvement in DMS performance (specifically at longer delays) when the M group were compared to the H group and also when the H group was tolerance tested and then stabilised on methadone.
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Interpretation
Although there are likely commonalities in the ways in which all opioids can affect cognitive performance, much can be learned from considering the distinctive features of each type of opioid and its effect on visuospatial memory. In this study, we have described significant differences in performance between the heroin, methadone and chronic pain groups. The H but not the M group differentially showed impairment in visual memory whereas both the H and M groups showed impairment in spatial memory. Importantly, the performance of the licit opioid exposed group was broadly similar to that of the HC group. However due to the significantly lower dose equivalence in the licit opioid group one needs to cautiously suggest that the impairments in visuospatial memory Heroin users presented with significant delayed memory impairments when compared to either M or P groups using a cross sectional comparison. These impairments diminished with a longer duration of stable methadone. Additionally, within-subject comparisons of participants who had used illicit heroin but had been transferred to a stable dose of methadone for only a few weeks also However, since DMS outcome impairment did increase significantly as a function of delay in the heroin group, the results are also suggesting that the impairment might also lie in higher order cognitive executive processes rather than solely as impairment in the memory storage process.
Additionally, tasks such as Paired Associates Learning (PAL) are associated with hippocampal function and may be highly sensitive to identify those with memory impairments.
Even though this study did not investigate the cognitive impairments observed in response to different opioids using molecular pharmacological techniques one still needs to be aware that However, there may be individual patients (e.g., those treated with high opioid doses, using illicit heroin or using non-opioid drugs frequently) that show deficits in spatial working memory. The strict methodology of our study attempted to minimise such effects. statistically non-significant. In this study we could not repeat cognitive testing in the healthy control and we could not recruit groups with similar socioeconomic status. It would be warranted for future studies as this will give a further confirmation of the cognitive improvement found in this study Finally we want to highlight that there is no literature to compare, if any, dose related cognitive effects between prescribed methadone, tramadol, codeine and/or combinations.
Limitations
Clinical Interpretation
This study identified opioid specific visuospatial memory impairments that need to be considered within the recovery-oriented treatment programmes for opioid dependent populations (Ekthiari et al. 2017). The visuospatial memory impairments will have implications for the successful outcomes of current non-pharmacological approaches, such as relapse prevention techniques and motivational enhancement therapies since all these interventions demand intact sophisticated encoding and retrieval strategies, visual processing and inhibition of irrelevant information. These approaches are reported to improve outcomes in individuals with opioid dependence when they are used to 
Tables
n/a n/a n/a
Days of heroin use (last 30 days) *
29.50(2.7)(n=24 ) n/a n/a n/a ns . Post hoc Bonferroni comparisons identified participants from the HEROIN group significantly making more errors than did: the HEALTHY CONTROL group in the 0 (**p<0.005), 4 (***p<0.001) and 12 second (***p<0.001) delay stages, the CHRONIC PAIN group for the 4 (*p<0.01) and 12 (**p<0.005) second delay stages and the METHADONE group for 0(**p< 0.005), 4 (**p<0.005) and 12 (***p<0.001) second delay stages.
Sim= Simultaneous condition, SD= Standard Deviation.
Figure 2:
A-Total errors in Spatial Span (SSP) task (Means and Standard Deviation). Overall participants significantly made more errors [F (3,102) =16.8, p<0.001]. Post hoc Bonferroni comparisons identified the HEROIN group participants significantly making more errors compared to the METHADONE (p<0.001) and HEALTHY CONTROL (p<0.005) groups. The total errors for the CHRONIC PAIN participants lay between those of the HEROIN, METHADONE and HEALTHY CONTROL participants and did not differ significantly from these three groups (p=1.0).
B-Span length in the SSP task (Means and Standard Deviation). Overall participants were significantly unable to recall successfully the longest sequence [F(3,101)=3.7,p<0 .01] with Post hoc Bonferroni comparisons identifying the METHADONE group as the group that significantly was less able to recall successfully the longest sequence compared to the HEALTHY CONTROL group (p<0.01).
